Medicine & Pharmaceuticals News
How Creative Biolabs Reshapes Next-Generation RNA Drug Development with an "End-to-End Strategy"
As the global biopharmaceutical industry once again reaches a structural turning point, an mRNA technology route extending from sequence design to preclinical research is being re-examined. Whether it is tumor immunotherapy, vaccines for infectious diseases, or treatments for cardiovascular and metabolic diseases, mRNA has become a "must-win battleground" in the R&D pipeline. "Now, mRNA research and development is no longer just about 'making an mRNA strand,' but rather predicting its structure, translation efficiency and immune stimulation intensity during the design phase," said a technical leader at Creative Biolabs. "The essence of R&D has shifted from trial and error step by step to chain optimization, and speed will determine which enterprises can remain in the game in the coming years." Winning at the Source: Sequence Design as the Foundation of mRNA Vaccine Development One of the most profound lessons for the industry after COVID-19 is that sequences determine everything. From codon optimization and UTR engineering to Cap modifications and secondary structure prediction, these early-stage steps directly impact stability, expression levels, and antigen presentation efficiency. Creative Biolabs' mRNA vaccine development service is now entering this "source capability." Through structure prediction, in vitro transcription system optimization, LNP formula design, and immune response assessment, this platform helps researchers screen out more promising candidate sequences at the early stage. "Many past failures weren't due to incorrect targets—the mRNA simply didn't express well enough," explained a scientist from the project team. "Building a more reliable structural model during sequence design can shorten development time by six to twelve months." RNA-Protein Interaction Analysis: The Hidden Variable Determining mRNA While the industry is still mired in the inertia that "producing mRNA" is enough to move forward, RNA-protein interaction analysis is becoming a key technology in the new round of competition. The fate of mRNA in the body is often determined by RNA-binding proteins (RBPs): half-life translation efficiency immune activation even tissue distribution Creative Biolabs' workflow integrates CLIP-seq, pull-down assays, and proteomics to reveal how a given mRNA behaves inside cells. In many cases, the effectiveness of mRNA is not constrained by the sequence itself but "kidnapped" by the proteins it binds to, the leader commented. "Such information is crucial before animal experiments but is often overlooked." One-Stop mRNA Therapy Development : Turning Fragmented Steps Into Deliverable Medicines Once sequence design and functional validation are completed, development often gets stuck in the most time-consuming yet crucial steps, such as manufacturing, delivery system design, and safety evaluation. To address this bottleneck, Creative Biolabs has established a complete chain covering: mRNA synthesis and purification LNP formulation development Stability and functional validation PK/PD studies Toxicology and safety assessment Full preclinical delivery "The biggest inefficiency in the industry now is the stitching together of different platforms," the leader pointed out. "What we are trying to do is to free the R&D team from the task of assembling fragments into a functional drug."
Gene Prediction Tools Market to reach USD 507.65 million by 2030, Demand for Accurate Computational Analysis Drive New Opportunities
Ace Therapeutics Introduces In Vitro Modeling Platform for Stroke Drug Screening
Creative Biolabs Launches an AI-Driven Antibody Platform to Accelerate Biopharmaceutical Research
- December 9, 2025Medicine & Pharmaceuticals
MergersAndAcquisitions.net Releases Healthcare/MedTech M&A Trends & Analysis Report Highlighting Rebound in Deal Activity
MergersAndAcquisitions.net today announced the release of its new Healthcare & MedTech M&A Trends & Analysis Report , a comprehensive review of global and North American transaction activity across the medical technology ecosystem. The report examines 24 months of deal flow, valuation trends, strategic acquisition themes, and private equity participation, giving corporate development teams, investors, and founder-operators clear visibility into where capital is moving—and why. The study analyzes movements across key sub-sectors including cardiovascular, neurovascular, urology/pelvic health, imaging and diagnostics, radiopharma, surgical robotics, and AI-enabled MedTech. It also includes case studies of high-profile acquisitions such as Johnson & Johnson’s purchase of Shockwave Medical, Stryker’s acquisition of Inari Medical, Boston Scientific’s acquisition of Axonics, and other cornerstone deals that shaped the recent cycle. “Despite the slowdown in 2023, the MedTech landscape has demonstrated remarkable resilience, and the rebound we’re now seeing is both broad-based and strategically motivated,” said Nate Nead, Managing Director at MergersAndAcquisitions.net . “The most active acquirers—both strategic and private equity—aren’t simply buying growth. They’re repositioning portfolios, expanding adjacencies, and accelerating access to technologies that will define the next decade of patient care. Our report is designed to give operators and investors a clear roadmap for how to think about timing, valuation, and competitive positioning as the cycle continues to strengthen.” Deal Activity Rebounds After 2023 Lull The report notes a meaningful uptick in M&A activity throughout 2024 and into 2025, fueled by: Improving interest-rate visibility and renewed confidence in credit markets A backlog of strategic initiatives paused over the previous 18 months A more balanced valuation environment, with premium multiples preserved in high-growth device categories Strong demand for tuck-in acquisitions supporting commercial scaling or technology expansion While mega-deals captured headlines, the report emphasizes that mid-market transactions—founder-led MedTech companies with $10M–$300M in revenue—are driving the most predictable volume and continue to command strong interest from both strategics and sponsors. “If you look beyond the billion-dollar transactions, you’ll see a very healthy middle market that never lost its underlying momentum,” Nead said. “These are businesses with strong clinical evidence, recurring revenue mechanics, and defensible IP. They fit squarely into the buy-and-build frameworks of private equity while also filling capability gaps for strategics under pressure to innovate faster.” Valuation Trends & Competitive Dynamics The new report outlines how valuation multiples have evolved across the MedTech ecosystem. High-growth categories such as structural heart, peripheral vascular intervention, neurovascular, and specialized diagnostics continue to trade at notable premiums, while more mature categories have stabilized at historically sustainable ranges. Key valuation insights include: Premium EV/Revenue and EV/EBITDA multiples in cardio-intervention and neurovascular segments Normalization in categories that surged due to pandemic-driven demand Increasing valuation spreads between companies with strong vs. weak reimbursement outlooks Heightened scrutiny on clinical evidence and regulatory certainty as gating factors in valuation The report also highlights the influence of the 2023 DOJ/FTC Merger Guidelines on transaction pacing, diligence rigor, and structural considerations—especially in concentrated niches where market definition and competitive impact require additional scrutiny. Strategic & PE Buyers Remain Highly Active The analysis identifies Johnson & Johnson, Stryker, Boston Scientific, Medtronic, Siemens Healthineers, Abbott, GE HealthCare, Edwards, BD, and Zimmer Biomet as among the most active corporate buyers over the past two years. Their acquisition strategies reflect a combination of adjacency stacking, portfolio rebalancing, and accelerated technology acquisition. Private equity participation also remains strong, especially across: Contract manufacturing (CMO/CDMO) Surgical/diagnostic consumables MedTech software and data platforms Specialized device companies with scalable footprints “What stands out most in this cycle is the intentionality behind the deals,” Nead said. “Strategics are buying with a clear sense of where clinical workflows are moving, how reimbursement is shifting, and where AI and robotics will unlock meaningful differentiation. Private equity, on the other hand, is building highly specialized platforms with operational rigor and defensible market positioning. Both groups are extremely thesis-driven right now.” Case Studies & Operator-Focused Takeaways The report includes sector-specific transaction case studies detailing: Enterprise value benchmarks Strategic rationales Commercial and R&D synergies Integration frameworks Market impact and forward-looking implications These insights are designed to help MedTech executives assess exit timing, prepare for buy-side expansion, and benchmark their company against prevailing market dynamics. “Founders and operators often underestimate how much timing and positioning matter,” Nead noted. “This report gives them a framework not just for evaluating their valuation potential, but for understanding the strategic logic that makes certain companies irresistible acquisition targets.” About MergersAndAcquisitions.net MergersAndAcquisitions.net provides middle-market companies, investors, and corporate buyers with buy-side and sell-side advisory , valuation analysis, diligence support, and integration planning. The firm’s Healthcare & Life Sciences practice serves founder-led MedTech companies, private equity sponsors, and strategic acquirers across the U.S. and abroad.
- December 5, 2025Medicine & Pharmaceuticals
Boston Functional Medicine Practitioner Content Marketing: Services Announced
Grand Exposure has introduced a new content marketing service designed to help functional medicine practitioners and professionals in the integrative healing arts across Boston and surrounding communities improve both traditional and AI-driven search visibility. The rollout comes in response to recent search engine algorithm updates that have made it harder for some practices to maintain previously strong online rankings. More information is available at https://grandexposure.clientcabin.com A spokesperson for Grand Exposure explained that the evolving online search environment is creating new challenges for practices that rely on consistent patient inquiries. “Maintaining a strong online presence is more complex than ever. AI-driven search tools prioritize verified sources, so practices without optimized content risk fading from the results patients actually see,” they said. Grand Exposure’s solution uses a three-part model called Create, Repurpose, and Distribute, which is the result of ongoing research into strategies for preserving online visibility amid rapid AI adoption and search engine overhauls. The process begins by clarifying each client’s core value proposition and mapping the search intent of prospective patients. From there, the team produces targeted content designed to address patient needs directly. That content is then adapted into multiple formats, including social media clips, infographics, slide presentations, podcast segments, and blog posts. According to Grand Exposure, this multi-format approach allows brands to reach a wider audience and enhances visibility across AI-organized search results and social platforms. Once developed, content is distributed across a curated network of reputable news sites, niche publications, and high-authority platforms. Being published on credible platforms generates measurable online signals that both traditional and AI-driven search tools cannot overlook, which can result in visibility improvements across multiple channels. The service also increases the likelihood of content being referenced by AI-driven answer engines, which are increasingly providing direct responses to user queries. By optimizing content for AI crawlers, Grand Exposure ensures that key information about a practice is accurately captured and surfaced. Each campaign is tailored to reflect real patient queries and highlight the unique strengths of each practice, helping practitioners maintain an authoritative online presence. Functional medicine practitioners interested in learning more are encouraged to visit https://grandexposure.clientcabin.com
- December 2, 2025Medicine & Pharmaceuticals
Delta Clinics UK Expands UK Presence, Surpasses More Than 10,000 Clients Milestone
Delta Clinics UK has recorded more than 10,000 clients, marking a significant milestone in its role within the UK’s plastic surgery sector. The achievement reflects a period of rapid growth for the clinic, which recently opened a second facility on Harley Street, a well-known centre for medical excellence in London. Delta Clinics UK delivers cosmetic surgery services with a focus on safety, patient care, and clinical expertise. The clinic provides an integrated approach that brings consultation, surgery, and recovery together under one roof. With established locations in Harley Street, and Finchley, Delta Clinics UK ensures patients can access treatments close to home while benefiting from consistent aftercare across all sites. The clinic is recognised for procedures such as tummy tucks, 360 Vaser liposuction , breast augmentation , and comprehensive mummy makeovers . The clinic has also introduced the 3D tummy tuck, an advancement on traditional abdominoplasty that targets not only the abdominal muscles but also the waist, hips, and flanks. By approaching body contouring from multiple angles, the technique is designed to deliver more proportionate and balanced results. Consultant Plastic Surgeon Hazem Alfie, who is registered with the GMC Specialist Register and a member of BAAPS, BAPRAS, and EBOPRAS, emphasised the significance of this moment. “Crossing the 10,000-client mark is not simply a number for us. It is a reflection of trust placed in our clinic and the responsibility we hold toward each patient,” he said. “Our priority has always been to deliver safe, effective, and carefully tailored surgery that respects both the physical and emotional aspects of every individual’s journey.” Operating within a very competitive market Delta Clinics UK has built a growing reputation supported by positive patient feedback. The clinic maintains a strong 4.9 Google rating, reflecting its combination of clinical expertise and patient-focused care. Plastic surgery has seen growing demand in the UK, driven both by advances in techniques and by shifting attitudes toward cosmetic treatments as part of personal well-being. Delta Clinics UK positions itself as part of this development, aligning surgical expertise with patient support systems. “Every procedure is about more than just physical change,” Mr Alfie added. “It is about addressing self-esteem, body image, and the personal goals that bring patients to us in the first place.” With more than 10,000 clients to date, Delta Clinics UK is now preparing for its next stage of expansion. The clinic’s stated long-term vision is to become a recognised leader in UK cosmetic surgery, offering a broader range of treatments while keeping its focus on safety, transparency, and quality outcomes. About Delta Clinics UK Delta Clinics UK is a UK-based plastic and cosmetic surgery provider with clinics in Harley Street and Finchley. The company offers a comprehensive range of procedures including tummy tucks, 360 Vaser liposuction, breast augmentation, mummy makeovers and various facial procedures. All services are delivered within owned facilities, allowing patients to receive consultation, surgery, and recovery care in one setting. With more than 10,000 clients to date, Delta Clinics UK is dedicated to patient safety, advanced surgical techniques, and consistent, high-quality outcomes across all treatments.
- November 30, 2025Medicine & Pharmaceuticals
Families Gain Clarity: Postmortem Pathology Expands Private Autopsy Services in St. Louis
This development, which includes the acquisition of state-of-the-art diagnostic equipment and an increase in specialized staffing, is designed to provide more accessible and timely answers for those grieving the loss of a loved one. The expansion directly addresses the community's growing need for Private Autopsies in St Louis , which can offer crucial information when official autopsies are not performed. For families facing unanswered questions surrounding a cause of death, these services provide an essential path toward understanding, closure, and peace of mind. The enhanced capacity allows Postmortem Pathology to reduce wait times and deliver comprehensive reports more efficiently. This investment strengthens the organization's ability to support families during a profoundly difficult time. The new equipment enhances diagnostic accuracy, while additional board-certified pathologists and support staff ensure that each case receives meticulous and compassionate attention. "When a family loses someone, the search for answers can be an overwhelming part of the grieving process," said Dan Lingamfelter, Lead Pathologist at Postmortem Pathology. "Our expansion is driven by a commitment to the St. Louis community. By increasing our capacity and technological capabilities, we can provide more families with the definitive, compassionate, and timely clarity they deserve." The private autopsy services offered by Postmortem Pathology are independent of coroner or medical examiner systems, giving families a dedicated option for investigating medical conditions, confirming clinical diagnoses, and addressing concerns about the circumstances of a death. About Postmortem Pathology Postmortem Pathology is a leading provider of Private Autopsy Service and postmortem examination services. Staffed by a team of board-certified pathologists, the organization is dedicated to delivering accurate, thorough, and compassionate diagnostic services to families seeking understanding and closure after the loss of a loved one.
- November 27, 2025Medicine & Pharmaceuticals
Pharmacy CCM & RPM Program Implementation With Physician Partnership Announced
CCM RPM Help has announced a pharmacy-physician collaboration model for Chronic Care Management and Remote Patient Monitoring programs under Medicare’s reimbursement structure. More information is available at https://ccmrpmhelp.com/contact The organization reports that pharmacies face shrinking margins and rising operational pressures. To remain financially sustainable, many are exploring clinically aligned revenue opportunities. CCM RPM Help's partnership model addresses this need by connecting pharmacies with physicians to deliver Medicare-approved Chronic Care Management and Remote Patient Monitoring services. The framework enables reimbursement for patient follow-ups, medication adherence support, and health data tracking for individuals managing chronic illnesses. Chronic Care Management supports patients living with two or more chronic conditions through structured monthly engagement. Pharmacies coordinate with physicians to meet Medicare’s time requirements while ensuring continuity of care between office visits. Remote Patient Monitoring programs utilize connected devices to collect vital signs and key health metrics from patients at home. Pharmacy teams review incoming data from tools such as blood pressure monitors, glucose meters, pulse oximeters, and weight scales to identify early signs of health concerns and notify providers when necessary. A company representative stated: "Pharmacies can partner with physicians to manage CCM and RPM programs—a Medicare-endorsed model that rewards pharmacies for clinical work they're already performing. By managing clinical services, pharmacies can earn tens of thousands in new revenue." The partnership model strengthens working relationships between pharmacies and physicians through shared care responsibilities, ultimately supporting consistent patient education and proactive health management. CCM RPM Help guides pharmacies through implementation, including workflow design, electronic health record coordination, staff training, and reimbursement setup. The organization ensures that processes integrate smoothly into existing operations while maintaining compliance with Centers for Medicare and Medicaid Services billing guidelines. Clinical staff receive training to reinforce medication adherence strategies and document care activities to meet regulatory standards throughout the program lifecycle. Founded by professionals with decades of experience in clinical operations, technology, and consulting, CCM RPM Help developed its services to support healthcare organizations seeking structured, scalable care coordination programs that improve patient outcomes. Pharmacies interested in implementing CCM and RPM partnership models can contact support through the details at: https://ccmrpmhelp.com/contact
- November 25, 2025Medicine & Pharmaceuticals
Simon Faynboym Recognized For Leadership And Measurable Mental Health Care Improvements With 2025 Global Recognition Award
Dr. Simon Faynboym received a 2025 Global Recognition Award for his continued excellence in psychiatry, the application of evidence-based treatments, and his leadership role in a network of mental health facilities serving diverse communities throughout Southern California. His responsibilities at a leading outpatient mental health provider demonstrate his ability to integrate patient care with operational systems that adhere to strict standards, even as the facility extends its reach and introduces new therapy options. The selection process for the award employed the Rasch model, creating measurable comparisons that included leadership, service, teaching, research, and innovation, rather than placing weight on any one field alone. Photo Credits Dr. Simon Faynboym This model allowed for a balanced review of professionals with different skills, favoring those with a record of steady results in multiple areas. Dr. Faynboym’s work includes reliable outcomes in developing policy, leading effective teams, and adapting guidance from research into practical steps for staff and patient benefit. Industry analysts predict that the mental health sector could reach $112.87 billion by 2030, a forecast that aligns with the growing demand for services and supportive resources used in conjunction with regular appointments. Clinical Leadership And Operational Integration Dr. Faynboym joined the organization during a period of early expansion, playing a significant role in organizing the structure as its services expanded into Los Angeles and Orange County. In these two regions, officials now report persistent staff shortages. The facility now stands among the foremost providers of transcranial magnetic stimulation, with new data showing that nearly 83 percent of patients report improvement, and more than half sustain their gains over time. He oversaw the opening of new locations and enforced requirements for checks and reliable treatment plans, responding to recruitment concerns that have increased across California in recent years. His leadership involved providing continuous support to various health teams, ensuring that clinicians engaged in regular training and case discussions to maintain consistent standards across multiple sites. Introducing Microsoft-based tools and standardized record-keeping has reduced the time required for administration, allowing staff to focus more on patient issues and meet documentation needs. Outcomes for repetitive transcranial magnetic stimulation programs highlight that relapse prevention rates can be as high as 85 percent at the 24-week review, which surpasses many medication-only approaches commonly used. Professional Advocacy And Educational Contributions Dr. Faynboym has led initiatives as a delegate of established associations like the American Medical Association, California Medical Association, and American Psychiatric Association, contributing to policy and reimbursement planning. His board membership in the Indiana State Medical Association represents a lasting commitment to organized medicine, aimed at closing service gaps identified in official assessments. Current estimates from California health planners show an urgent requirement for thousands of psychiatry professionals to manage patient loads in the coming years, and coordinated advocacy is a necessary response to these gaps. He has appeared as a contributing expert in publications that help clinicians and patients navigate new evidence regarding treatment options and interventions. Patient review awards earned from multiple platforms and high satisfaction scores demonstrate an ability to maintain clear professional standards while effectively communicating with patients. His research output, which focuses on topics such as the overlap between mental health and chronic medical symptoms, provides further evidence of his professional influence and expertise. Final Words Dr. Simon Faynboym’s work demonstrates reliability in guiding operational groups, prioritizing consistent patient service, and supporting knowledge sharing, each of which is evident through the collected results at several clinic locations. Actions at the mental health organization, active support for institutional partners, and a commitment to education reflect the understanding that mental health care is shaped by practical leadership, ongoing learning, and systematic problem-solving. California’s investment, approaching $14 billion, prioritizes access, adequate staffing, and improvements that reach across diverse communities and respond to the direct needs identified in recent studies and regional reviews. Alex Sterling, spokesperson for the Global Recognition Awards, explained that "Dr. Simon Faynboym demonstrates a rare combination of disciplined leadership, steady operational judgment, and genuine commitment to patient welfare that this recognition is meant to highlight." These remarks highlight that the recognition is based on a sustained record of effecting practical change and setting an example for clinicians and health administrators, who face similar challenges. A 2025 Global Recognition Award confirms that continued work in these areas contributes to better patient outcomes, new developments in care, and higher team morale in diverse settings. About Global Recognition Awards The Global Recognition Awards is an international organization that recognizes exceptional companies and individuals who have made significant contributions to their respective industries.
- November 25, 2025Medicine & Pharmaceuticals
Creative Biolabs Strengthens Solid Tumor ADC Strategy with Three High-Value Target Additions
With growing interest in ADC development all over, Creative Biolabs, through an expansion to its portfolio of tumor targets, has announced new antibody development capabilities for three high-value solid tumor targets: DLL3, PTK7, and FAP. This expansion adds multiple dimensions of ADC target resources—tumor cells, tumor stemness, and the tumor microenvironment (TME)—supporting researchers and biopharmaceutical companies as they build the next generation of precision therapies. In ADC development, the choice of target has increasingly become a pivotal determinant of clinical advancement. With a growing shift from traditional hematologic cancers to solid tumors, over half of which historically display little or no responses to treatment, new targets with high selectivity and strong internalization capacity are increasingly attracting interest. Among them, DLL3—known for its highly tumor-specific expression in small cell lung cancer (SCLC) and neuroendocrine tumors—has long been recognized as a strong candidate for ADC development. To help researchers improve early-stage target assessment and antibody screening efficiency, the company has upgraded its related research modules and officially launched its DLL3 antibody development solution. "One of the reasons DLL3 seems to be back in the spotlight is its distinctive expression pattern," remarked a scientist focused on the ADC platform at Creative Biolabs. "We're supporting an increasing number of clients who are investigating DLL3 antibodies that have improved internalization and potential ADC application, which will ultimately provide a breakthrough for solid tumors." At the same time, the company has introduced antibody development capabilities for PTK7. As an atypical receptor tyrosine kinase highly expressed in colorectal cancer, gastric cancer, and multiple drug-resistant tumors, PTK7 is widely regarded as a promising ADC target. Creative Biolabs has optimized its antibody screening and cellular internalization validation workflows to help clients generate anti-PTK7 antibodies with improved affinity and specificity. "PTK7's value lies not only in its broad expression across malignant tumors," a senior researcher commented, "but also in its role in regulating tumor invasiveness and the Wnt signaling pathway, making it a strong candidate for differentiated ADC development." Notably, the expansion also includes FAP, a representative TME-related target. Abundantly expressed on cancer-associated fibroblasts (CAFs), FAP has become an important entry point for ADC strategies aimed at overcoming physical barriers in solid tumors. Unlike traditional tumor-cell-centric approaches, FAP-targeting ADCs may remodel the tumor stroma and improve drug penetration, thereby enhancing therapeutic synergy. "The combination of DLL3, PTK7, and FAP represents a strategic expansion informed by our long-standing experience in ADC services," a Creative Biolabs expert stated. He further noted that, as the global ADC market rapidly grows, multi-target strategies will become an important way for biopharma companies to build competitive differentiation. About Through this expanded target portfolio, Creative Biolabs hopes to provide more support for partners across early ADC research, lead antibody screening, engineering optimization, and pharmacological evaluation, helping to speed progress during the pipeline process.
- November 24, 2025Medicine & Pharmaceuticals
CD Bioparticles Launches New Portfilio of Custom Services to Advance Beads-Based Cell Isolation
With years of experience in the pharmaceutical and life science sectors, CD Bioparticles has announced the launch of its comprehensive custom services for Beads-Based Cell Isolation utilizing Magnetic Activated Cell Sorting (MACS) technology. These new offerings will help scientists streamline research and clinical workflows, as the key parameters such as purity, viability and recovery can be provided according to their specific requirements. MACS is a highly specific and rapid cell sorting technology based on magnetic particles that is widely used in immunology, stem cell research, oncology and clinical medicine. It employs antibody-conjugated magnetic particles to capture antigens on the surfaces of target cells, causing them to adhere to the sidewalls of a magnetic field. This separates unlabelled cells without bound magnetic particles from the cell suspension. To meet the growing needs of scientists, CD Bioparticles now offers customized antibody-conjugated magnetic nanoparticles and cell sorting validation services. The diameter of the magnetic nanoparticles and the antibody conjugation method can both be tailored to specific requirements. For cell sorting validation, CD Bioparticles can provide relevant data on key parameters such as purity, viability and recovery rate. The magnetic particles supplied by CD Bioparticles are engineered for optimal performance, ensuring minimal disruption to cells. They offer significant advantages in various biological fields, primarily due to their superior handling and performance characteristics. Their nanoscale size and dextran coating ensure excellent biocompatibility and minimal impact on cell function and viability, while also contributing to low non-specific binding. These particles are designed for simple and efficient separation, eliminating the need for expensive specialist equipment. Furthermore, they are easy to conjugate and, as they are suitable for high-temperature sterilisation prior to conjugation, they are better suited to aseptic control. This combination of features results in high cell purity and recovery. Their broad utility makes them ideal for a range of applications, including stem cell and cancer research, immunology, diagnostics, clinical applications, drug development and quality control in cell manufacturing. CD Bioparticles' custom services provide researchers with critical flexibility. The company specializes in the synthesis of basic magnetic nanoparticles in a range of diameters, including 50 nm and greater than 200 nm, to perfectly match clients' experimental needs. For the 50 nm particles, separation requires a dedicated sorting column and matching magnetic frame, whereas particles with a diameter greater than 200 nm can be separated using an ordinary magnet without a sorting column. Additionally, CD Bioparticles provides antibody conjugation upon request, enabling researchers to select the desired coupling method, including chemical and biological conjugation based on streptavidin (SA)-biotin. CD Bioparticles also offers SA magnetic nanoparticles and biotinylated antibodies individually for flexible ratio adjustment. Furthermore, clients can request cell-sorting validation, for which CD Bioparticles can provide comprehensive data on the positive rate, viability and recovery for both the flow-through and retained fractions. To know more information about the new services, or to contact the CD Bioparticles team for a consultation, quote, or proposal, please visit https://www.cd-bioparticles.com/s/Beads-Based-Cell-Isolation_28.html . About CD Bioparticles CD Bioparticles is a leading manufacturer and supplier of various nanoparticles, microparticles, and coatings for R&D as well as commercialization across different application areas, including in vitro diagnostics, biochemistry, cellular analysis, cell separation, and immunoassay. The company also offers various custom services, including chemical surface-functionalization, fluorescent modification, antibody immobilization, as well as nucleic acid and oligo conjugation to meet client specifications.
- November 24, 2025Medicine & Pharmaceuticals
STEMart Launches Comprehensive In Vitro Chromosome Aberration Test Service to Bolster Medical Device Safety and Compliance
STEMart, a US-based provider of comprehensive services for all phases of medical device development, has announced the launch of its In Vitro Chromosome Aberration Test service. This critical genetic toxicology assessment is essential for manufacturers seeking global regulatory clearance by evaluating the clastogenic potential of medical devices and materials. Genotoxicity testing involves evaluating the risk that test substances will induce gene mutations or chromosomal damage, using multiple in vitro and in vivo bacterial and mammalian cell testing systems. As a specialist in the medical device services sector, STEMart offers a range of diverse genotoxicity and biocompatibility testing solutions, including the Bacterial Reverse Mutation Test (Ames) and the In Vitro Mouse Lymphoma Assay TK. These solutions are designed to meet the varied testing needs and requirements of clients. STEMart strictly adheres to OECD guidelines revised for the medical device sector and conducts testing under Good Laboratory Practice (GLP) conditions. The In Vitro Chromosome Aberration Test is performed according to the rigorous standards of OECD Guideline for the Testing of Chemicals, Test No. 473, and is a core requirement within the ISO 10993-3 biocompatibility standard. The aim of this assay is to identify chromosomal structural abnormalities, including deletions, breaks and exchanges, that could potentially be induced when extracts from medical devices come into contact with mammalian cells. The results of this test provide critical data for assessing the genetic safety of new products. STEMart now offers in vitro chromosome aberration testing to evaluate the ability of medical devices to cause structural aberrations in mammalian cell chromosomes. This testing can be conducted under GLP (Good Laboratory Practice) or non-GLP conditions. The assay can be performed using either human pulmonary alveolar epithelial cells (HPBLs) or established cell lines, such as Chinese hamster ovary (CHO) cells. This test is applicable to medical devices intended for permanent or long-term patient contact, or for contact with blood. The testing can be conducted in two ways, including the short-term exposure (4 hours) with metabolic activation (S9) conditions, or long-term exposure (21 or 24 hours) without S9 conditions. Manufacturers can use this approach to comprehensively evaluate potential mutagenic effects. In addition, GLP-compliant and non-GLP options are available to meet diverse client requirements. STEMart also provides the final report that includes the detailed methodology, the raw data and expert interpretation to clients, supporting manufacturers to meet the regulatory goals and minimize the compliance risks. STEMart offers the chromosomal aberration test to evaluate whether a medical device compound could cause chromosomal abnormalities. To learn more about these services and other medical device testing solutions, or to consult with the experts at STEMart, please visit https://www.ste-mart.com/in-vitro-chromosome-aberration-test.htm . About STEMart STEMart is an industry-leading eCommerce platform incorporated with an extensive global footprint and a broad portfolio of more than 10,000 products. It aims to provide better lab materials, medical instruments and consumables, excellent technologies, and high-quality services to global customers in the fields of science, technology, and engineering, from the discovery stage upward to the manufacturing process. STEMart is dedicated to enhancing research and biotech production with simpler and safer protocols to access better health worldwide.
- November 24, 2025Medicine & Pharmaceuticals
Creative Diagnostics Launches Comprehensive Suite of HSV Animal Model Services to Support Antiviral Research
As an expert in providing solutions to assist virology and microbiology research, Creative Diagnostics has announced the launch of its Herpes Simplex Virus (HSV) Animal Model services to the research community. These HSV animal models can provide scientists with critical in vivo tools to investigate the complex biology, pathogenesis, and immune response associated with HSV-1 and HSV-2, which will help to accelerate the development of new therapeutics and vaccines. HSV is primarily classified into two types, HSV-1 and HSV-2. HSV-1 and HSV-2 are among the most common human viruses globally. HSV-1 typically infects the mucosal epithelium of the oral cavity or eyes, causing cold sores or herpetic stromal keratitis (HSK), while HSV-2 is the primary cause of genital herpes. HSK is a form of corneal inflammation that can lead to blindness, and it originates from a primary HSV-1 infection followed by viral latency in sensory and autonomic ganglia. Most cases result from reactivation of the latent infection. Animal models are crucial for investigating HSK pathogenesis and therapeutic approaches. Mice and rabbits are the most commonly used animal models for studying HSV-1 latency, reactivation and recurrence. As a leading service provider in infectious disease research, Creative Diagnostics is dedicated to advancing the understanding of the herpes simplex virus by developing reliable animal models. The company's mission is to provide clients with cutting-edge tools and innovative methodologies to explore the complex biological mechanisms of HSV, including its molecular structure, pathogenic pathways, disease progression and immune defence systems. An ideal HSV animal model must possess key characteristics such as an immune system identical to that of humans, reproductive tract anatomy consistent with humans, and cellular components that interact with HSV immune evasion mechanisms corresponding to human cells. Creative Diagnostics' research team has successfully developed a series of animal models specifically engineered for HSV research. These include the HSV vaginal infection mouse model, the HSV brain infection mouse model, the HSV-induced rabbit keratitis model and the HSV-induced guinea pig skin injury model. Each model is meticulously designed to balance unique advantages with inherent limitations. Leveraging an advanced animal model technology platform, Creative Diagnostics offers multiple HSV latent infection inoculation protocols, including intranasal, digital, corneal scratch, tail vein, and tooth extraction inoculations. Models can be customized to meet specific research requirements by adjusting key experimental parameters such as the animal species, age, genotype, the route of infection, the viral serotype, strain and dose. Creative Diagnostics offers comprehensive services to support enterovirus animal model research. These services include study design and implementation, pathological analysis, immunological response profiling, in vivo pharmacokinetic studies and efficacy-toxicity assessments. Researchers can use these services to investigate acute, latent and recurrent HSV-1 and HSV-2 diseases, explore the precise mechanisms of HSV-mediated pathologies and develop and evaluate therapeutic agents and vaccines against HSV infection. Creative Diagnostics is committed to empowering scientists to pioneer new approaches to HSV prevention, diagnosis and therapeutic interventions. For more information on these models or related innovative solutions for preclinical research involving infectious diseases, please visit https://antiviral.creative-diagnostics.com/hsv-animal-model.html . About Creative Diagnostics Headquartered in New York, Creative Diagnostics is a consulting and experimental service provider specializing in virology and microbiology. The company provides comprehensive solutions to conquer obstacles in virology and microbiology research, from high-security infrastructure provision, biosafety regulation elucidation, to expert viral system assistance.
- November 20, 2025Medicine & Pharmaceuticals
Comstock Health Offers Free Open Enrollment Policy Reviews for Utah Residents
Salt Lake City, UT — Comstock Health Insurance, a leading health insurance brokerage serving thousands of clients across Utah, has announced that founder and licensed agent Christopher Comstock will offer free health insurance policy reviews during the 2026 Open Enrollment period. This initiative is part of ComstockHealth’s ongoing commitment to improving client support and ensuring individuals, families, and small businesses have access to the best coverage options available. With offices in both Salt Lake City and Park City Utah, ComstockHealth continues to expand its presence and resources to better meet increased demand during the busy enrollment season. “We’re proud to serve the Salt Lake and Park City Utah communities and want to be fully accessible during open enrollment,” said Comstock. “With so many insurance options, price increases, and recent industry changes, reviewing your policy with a professional can make a significant difference.” ComstockHealth has earned a strong reputation for helping clients navigate complex health insurance decisions. Known for personalized service and award-winning support—including recognition as Insurance Company of the Year—the firm has helped thousands of Utah residents secure tailored, cost-effective health insurance plans. By offering free policy reviews, Comstock Health aims to help clients: Understand how upcoming insurance changes may affect their coverage Compare plan options based on their health needs and financial goals Identify cost-saving opportunities and available subsidies Select plans that provide strong protection at a reasonable premium Comstock notes that the health insurance landscape has evolved significantly: “Competition in the small-business and individual markets has opened new opportunities that didn’t exist even five years ago. This makes it even more important to review coverage during open enrollment.” The complimentary service is available to small business owners, families, individuals, and anyone needing expert health insurance guidance. For more information or to schedule a free policy review, visit: comstockhealth.com
ALL NEWS
- Daniel Yomtobian on the Importance of Responsible Brand Campaigns During a Global Pandemic
- Flower Atelier & Co. Shares New Year Floral Creations for Warm and Meaningful Celebrations
- EduTrading Launches Practical Financial Education Platform Focused on Real-World Trading Skills
- IVF Injection Strengthens Access to Fertility and Hormonal Medicines Through Trusted Online Healthcare Platform.
- Mobile Message Fast-Tracks Sender ID Applications
- Curated Fashion for the Modern Shopper: How AsLook is Redefining Online Style
- Financial Services– Fiduciaire Luxembourg Expands Strategic Finance and Fiduciary Advisory Services for International Businesses
- Napoli Shkolnik Wins Top Settlement in the Annual Report of Class Action Review 2025 for Excellence in Mass Tort Litigation
- Mark "Almachize" Salazar Announces Launch of New Book "Internet Money"
- New Review Platform Transportvibe Helps Consumers Navigate Auto Transport With Verified Information
- Sofasia Expands International Reach With New Custom Modular Floor Sofa Collections
- Revolutionizing Lease Accounting with AI: An Exclusive Interview with Elena Moseyko, Founder of LedgrAI
- Safeeds Auto Transport Launches New Customer Policy with 7-Day Rate Guarantee to Combat Hidden Fees
- dotCMS Named a Major Player in the IDC MarketScape: Worldwide AI-Enabled Headless CMS 2025 Vendor Assessment
- Matthias Scharf's Leadership in Transforming AI, Cloud, and Computer Vision into Business Value
- EuroProBasket Brings European Pro Basketball Pathway to the U.S. as Athlete Debuts in EuroCup
- TimelyEstate Announces Exclusive Interview with Brian Ferdinand: 2026's Top Trailblazer in Public and Private Equity Markets”
- Flower Atelier & Co. Shares Seasonal Floral Offerings for Thanksgiving
COMMUNICATE. COMMAND. COMMERCE.
Lead the conversation of your brand & win more customers with MarketersMEDIA Solutions.
Explore Now
Google
RSS